undamentalytics Newsletter
Sign in

Zevra Therapeutics, Inc. cash flow statement

In fiscal 2025, Zevra Therapeutics, Inc.'s operations generated −$1.6m of cash; it spent $835,000 on capital projects, leaving free cash flow of −$2.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−4−15−20−54−24−210−19−34−70−233
Depreciation and amortisation000000011641
Stock-based pay002642246151313
Capital spending000000000011
Free cash flow−4−15−20−54−24−210−19−34−70−233
Free cash flow after stock pay−5−15−23−61−28−48−23−40−85−1519
Share buybacks—————03530——
Shares issued———5———06650—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: NAII vs ZVRANAGE vs ZVRAHRTX vs ZVRAETON vs ZVRA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Zevra Therapeutics, Inc.